List of Excipients in Branded Drug ZIPRASIDONE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing ZIPRASIDONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	ziprasidone hydrochloride	0615-7703	ALCOHOL
NCS HealthCare of KY Inc dba Vangard Labs	ziprasidone hydrochloride	0615-7703	AMMONIA
NCS HealthCare of KY Inc dba Vangard Labs	ziprasidone hydrochloride	0615-7703	ANHYDROUS LACTOSE
NCS HealthCare of KY Inc dba Vangard Labs	ziprasidone hydrochloride	0615-7703	BUTYL ALCOHOL
NCS HealthCare of KY Inc dba Vangard Labs	ziprasidone hydrochloride	0615-7703	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in ZIPRASIDONE HYDROCHLORIDE?

# Of NDCs	Excipient
22	ALCOHOL
48	AMMONIA
14	AMMONIUM CHLORIDE
25	ANHYDROUS LACTOSE
22	BUTYL ALCOHOL

Ziprasidone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Ziprasidone hydrochloride has two established dosage-form platforms: oral capsules and intramuscular injection. The oral product depends on a simple solid-dose excipient system but has a major food-effect constraint. The injectable product depends on sulfobutyl ether beta-cyclodextrin sodium, a higher-value solubilizing excipient with greater technical and manufacturing barriers. Commercial opportunity is strongest in generic capsule supply, food-effect mitigation, excipient qualification, injectable technology, and differentiated delivery systems.

What dosage forms contain ziprasidone hydrochloride?

Ziprasidone is marketed primarily as ziprasidone hydrochloride monohydrate for oral capsules. The injectable product uses ziprasidone mesylate trihydrate rather than the hydrochloride salt.

Product	Active form	Route	Principal formulation issue	Reference product
Geodon capsules	Ziprasidone hydrochloride monohydrate	Oral	Low aqueous solubility and clinically important food effect	Pfizer Geodon
Geodon injection	Ziprasidone mesylate trihydrate	Intramuscular	Parenteral solubilization and reconstitution	Pfizer Geodon
Generic capsules	Ziprasidone hydrochloride monohydrate	Oral	Bioequivalence, dissolution, content uniformity, food-effect control	ANDA products
Generic injection	Ziprasidone mesylate trihydrate	Intramuscular	SBECD supply, sterile processing, reconstitution performance	ANDA products

The capsule strengths are 20 mg, 40 mg, 60 mg and 80 mg. The injection is supplied as a 20 mg vial for intramuscular administration after reconstitution with sterile water for injection.[1]

What excipients are used in ziprasidone hydrochloride capsules?

The principal excipients in the branded capsule formulation are lactose monohydrate, pregelatinized starch and magnesium stearate. The capsule shell contains gelatin and colorants. Exact color systems vary by strength and manufacturer.[1,2]

Excipient category	Typical role in ziprasidone capsules	Commercial relevance
Lactose monohydrate	Diluent and bulk carrier	Low-cost, widely available, but relevant to lactose-intolerant patients
Pregelatinized starch	Binder, filler and disintegration aid	Supports capsule-content uniformity and dissolution
Magnesium stearate	Lubricant	Controls powder flow and manufacturing ejection
Gelatin	Hard capsule shell	Conventional, low technical risk
Titanium dioxide and colorants	Opacity and strength identification	Regulatory and supply-chain control point

The capsule formulation is commercially attractive because it does not require a complex multiparticulate system, lipid vehicle or specialized coating process. The core development challenge is not excipient novelty. It is achieving consistent exposure against a drug whose absorption is materially affected by food.

Why is the food effect the main oral formulation problem?

Ziprasidone exposure increases substantially when taken with food. The FDA label recommends administration with a meal of at least 500 calories, regardless of fat content.[1] This instruction creates adherence risk and gives formulation developers a clear differentiation target.

The food effect may reflect a combination of limited aqueous solubility, dissolution constraints and gastrointestinal conditions that improve drug solubilization after food intake. A capsule that reduces dependence on meal composition could offer clinical and commercial value, even if the active ingredient is off-patent.

Potential formulation approaches include:

1. Amorphous solid dispersions using polymers such as copovidone, hypromellose acetate succinate or hydroxypropyl methylcellulose.
2. Spray-dried dispersions designed to increase apparent solubility.
3. Lipid-based formulations using medium-chain triglycerides, mono- or diglycerides, surfactants and self-emulsifying systems.
4. Nanocrystalline or micronized ziprasidone.
5. Cyclodextrin complexes for oral solubilization.
6. Supersaturating formulations with precipitation inhibitors.
7. Modified-release systems that separate drug release from meal-dependent gastrointestinal conditions.

Each approach has a different regulatory and manufacturing profile. A conventional capsule with improved dissolution may be easier to develop than a lipid or amorphous system, but it may not eliminate the food effect. A new formulation would likely require clinical pharmacokinetic work beyond a standard ANDA pathway if it changes exposure under fed and fasting conditions.

Which excipients have the greatest commercial opportunity?

Sulfobutyl ether beta-cyclodextrin sodium

The injectable product uses sulfobutyl ether beta-cyclodextrin sodium, commonly known as SBECD, to solubilize ziprasidone for intramuscular injection. The marketed vial also contains mannitol.[1]

SBECD is the most strategically important excipient in the ziprasidone portfolio. It is a functional excipient rather than a passive filler, and its use can create barriers in:

• Excipient grade qualification
• Impurity and residual solvent control
• Bacterial endotoxin control
• Sterile manufacturing
• Container-closure compatibility
• Reconstitution time
• Extractables and leachables
• Supply continuity

The commercial opportunity is strongest for suppliers that can provide injectable-grade SBECD with regulatory documentation, batch consistency and global compendial support. A supplier with an established DMF or comparable regulatory package has an advantage over a commodity excipient distributor.

Mannitol

Mannitol provides bulking and tonicity support in the injectable formulation. It is widely available and has lower strategic value than SBECD. The opportunity lies in sterile injectable grades, validated low-endotoxin supply and reliable particle or solution performance rather than differentiated chemistry.

Lactose and pregelatinized starch

These excipients have limited margin potential because they are widely supplied and readily substituted. Their commercial value is tied to reliable supply, low foreign-matter risk, consistent particle-size distribution and support for generic capsule manufacturing.

Lubricants and capsule-shell materials

Magnesium stearate, gelatin, titanium dioxide and capsule colorants are mature categories. Suppliers can compete through quality systems, regional availability, vegetarian or non-animal capsule options and rapid regulatory support. These products do not normally create a strong barrier to entry.

How should a generic company design a ziprasidone capsule?

A conventional generic strategy should begin with a formulation close to the reference product. The target is not maximum excipient novelty. It is reproducible in-vitro performance and pharmacokinetic equivalence.

Critical development variables include:

• API particle-size distribution
• Crystal form and hydrate state
• Blend uniformity at low drug load
• Lubrication time
• Capsule fill weight
• Dissolution across pH conditions
• Stability under humidity stress
• Fed and fasting bioequivalence
• Drug release after different meal conditions

Ziprasidone capsules contain a relatively high drug load at the 80 mg strength but a lower drug load at 20 mg. The lower strength can create greater content-uniformity risk if API flow and blend segregation are not controlled.

Pregelatinized starch can support disintegration and powder binding, but excess lubricant or over-lubrication can slow dissolution. Lactose grade selection also matters. Spray-dried lactose may improve flow, while anhydrous or monohydrate alternatives can change compaction, moisture behavior and dissolution.

A manufacturer seeking a low-cost product should generally avoid unnecessary excipient changes. A manufacturer seeking differentiation should focus on reducing the meal requirement, supporting smaller capsules, or enabling a more consistent exposure profile.

What formulation patents can protect improved ziprasidone products?

Patent protection for an improved ziprasidone formulation would typically focus on one or more of the following:

Patent subject	Potential claim scope	Commercial value
Amorphous ziprasidone	Solid-state form and stabilization	Can protect composition and process
Particle engineering	Nanoparticles, micronized API or defined particle-size ranges	May improve dissolution
Solid dispersion	Polymer, solvent system and loading range	Can target food-effect reduction
Lipid formulation	Oils, surfactants and precipitation inhibitors	May improve fed/fasted consistency
Cyclodextrin complex	Cyclodextrin type, ratio and preparation method	Relevant to oral and injectable solubilization
Modified release	Matrix, coating or multiparticulate dosage form	Can support differentiated dosing
Injectable composition	SBECD concentration, pH, tonicity and reconstitution profile	Protects a higher-barrier sterile product
Method of use	Administration with defined meal, dose or patient population	Potentially narrower and litigation-sensitive

The strongest formulation patents usually combine composition limitations with measurable performance requirements, such as dissolution, particle size, supersaturation duration or pharmacokinetic parameters. Broad claims based only on the presence of a conventional excipient are more vulnerable to validity challenges.

What is the FDA regulatory status of ziprasidone?

Ziprasidone was approved by the FDA as Geodon capsules in 1998 and as an intramuscular injection in 2001.[1] The oral product is an approved small-molecule drug subject to the ANDA pathway for generic competition. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.

The injectable product has a more demanding development profile because the applicant must control sterility, endotoxins, reconstitution, particulate matter, container closure and the SBECD-containing formulation.

FDA regulatory priorities for a generic ziprasidone product include:

• Correct active salt and strength
• Matching dosage form and route
• Comparable dissolution
• Bioequivalence under FDA-required conditions
• Adequate stability data
• Control of nitrosamines and other organic impurities where applicable
• Acceptable container-closure systems
• Complete inactive-ingredient justification for parenteral products

Inactive ingredients in an injectable product receive greater scrutiny than those in a conventional oral capsule because route-specific safety and tolerability are directly implicated.

What is the Orange Book and exclusivity status of ziprasidone?

The original Geodon exclusivity period has expired, and ziprasidone is a mature generic market. The primary commercial issue is therefore not basic molecule exclusivity. It is competition among approved generic manufacturers, product availability, manufacturing cost and differentiated formulations.

The Orange Book should be reviewed for current listed patents, pediatric exclusivity history, reference-product designation and any active patent certifications.[3] Historical patent protection for the original product does not automatically protect a later formulation, capsule-shell system or injectable presentation.

A company developing a new ziprasidone formulation should conduct a separate freedom-to-operate review covering:

• Original compound patents
• Salt and polymorph patents
• Crystal-form patents
• Process patents
• Capsule and solid-dispersion patents
• Injectable SBECD composition patents
• Method-of-use patents
• FDA-listed patents for the relevant reference product

Are Paragraph IV challenges relevant to ziprasidone?

Paragraph IV litigation is most relevant when an ANDA applicant identifies an unexpired Orange Book patent and certifies that the patent is invalid, unenforceable or will not be infringed. For a mature drug such as ziprasidone, the principal early-entry risks typically arise from formulation, method-of-use or later-issued patents rather than the original compound patent.

A generic applicant should assess:

1. Whether the patent is listed against the exact reference product.
2. Whether the claims cover the proposed capsule or injection.
3. Whether a non-infringement position can be based on excipient concentration, process conditions or dosage form.
4. Whether the patent has pediatric or regulatory exclusivity attached.
5. Whether the patent owner has a history of filing infringement actions against ANDA applicants.

The risk profile is usually lower for a conventional capsule that follows the reference formulation and does not rely on a patented performance feature. It rises for food-effect-reducing systems, new solid states and long-acting or modified-release products.

What manufacturing and intellectual-property barriers affect injectable ziprasidone?

The injectable product has higher manufacturing barriers than capsules. SBECD must be controlled for identity, degree of substitution, residual impurities, endotoxin and bioburden. Sterile production adds aseptic-processing or terminal-sterilization constraints, depending on the product design.

The key barriers are:

• Qualified SBECD source
• Sterile fill-finish capacity
• Low particulate burden
• Stable reconstituted solution
• Consistent vial fill
• Reconstitution within label specifications
• Validated analytical methods
• Container-closure integrity
• Regulatory history for the excipient

These barriers can reduce the number of credible suppliers even when the active ingredient is widely available. A contract development and manufacturing organization with sterile capacity and experience with cyclodextrin formulations may have a stronger commercial position than a low-cost API supplier.

How does ziprasidone compare with competing antipsychotic products?

Ziprasidone competes with oral and long-acting antipsychotics including risperidone, paliperidone, aripiprazole, olanzapine, quetiapine and lurasidone.

Product category	Ziprasidone position	Excipient opportunity
Generic oral antipsychotics	Low-cost, mature competition	Manufacturing efficiency and food-effect reduction
Long-acting injectables	Ziprasidone lacks a comparable established long-acting product	Long-acting delivery could create substantial differentiation
Atypical antipsychotics with less food dependence	Competitive disadvantage for adherence-sensitive patients	Formulation work focused on fasting exposure
Acute injectable antipsychotics	Geodon injection has established hospital use	Injectable SBECD supply and sterile manufacturing
Branded differentiated products	Lower commercial investment in conventional ziprasidone	New delivery, adherence or tolerability positioning

A long-acting ziprasidone formulation would have the largest potential strategic value, but it would require substantial formulation, pharmacokinetic and clinical development. It would also face competition from established long-acting aripiprazole and paliperidone products.

What revenue exposure and licensing opportunities exist?

Ziprasidone’s conventional oral market is generally a price-competitive generic opportunity. Revenue exposure depends on sales volume, payer concentration, manufacturing cost and supply reliability rather than molecule exclusivity.

Potential licensing targets include:

• Polymer-based amorphous solid-dispersion technology
• Lipid-based oral delivery platforms
• Nanocrystal manufacturing
• Cyclodextrin formulation know-how
• Long-acting injectable depots
• Sterile SBECD supply agreements
• Alternative capsule systems for allergen, dietary or geographic requirements

The most defensible licensing assets are technologies that solve the food-effect problem, improve adherence or create a differentiated injectable product. Commodity lactose, starch and magnesium stearate supply contracts are commercially useful but usually do not justify substantial royalty economics.

What generic launch scenarios exist for ziprasidone?

Conventional oral capsule launch

This is the lowest-risk scenario. The product uses established excipients and targets ANDA approval. Competition is likely to center on price, channel access and supply reliability.

Food-effect-reduced capsule

This product could command a higher price if clinical data show more consistent exposure without a 500-calorie meal. The regulatory pathway may be more complex because the formulation could no longer be a straightforward pharmaceutical equivalent.

Generic injectable launch

This scenario offers a higher technical barrier and potentially better pricing than capsules. SBECD sourcing and sterile manufacturing are the principal execution risks.

Long-acting formulation launch

This is the highest-value but highest-risk scenario. It could create new intellectual property and clinical differentiation, but development would resemble a new product program rather than a conventional generic launch.

Key Takeaways

• Ziprasidone capsules use a conventional excipient system based on lactose monohydrate, pregelatinized starch and magnesium stearate.
• The principal oral formulation problem is the requirement to take ziprasidone with a meal of at least 500 calories.
• SBECD is the most commercially significant excipient in the injectable product.
• Generic capsule development is technically manageable but highly price competitive.
• Generic injectable development has higher barriers because of sterile processing, SBECD qualification and reconstitution control.
• The strongest new-product opportunity is a formulation that reduces food dependence, improves adherence or enables long-acting delivery.
• Conventional ziprasidone molecule exclusivity has expired; commercial protection now depends on formulation, process, method-of-use and manufacturing advantages.
• Biosimilar risk is not relevant because ziprasidone is a chemically synthesized small molecule, not a biologic.
• Paragraph IV exposure is most relevant to later formulation or method-of-use patents.
• Supplier opportunities are strongest in injectable-grade SBECD, sterile fill-finish and formulation platforms that address solubility and food effect.

FAQs About Ziprasidone Hydrochloride Excipients and Commercial Strategy

What is the most important excipient in injectable ziprasidone?

Sulfobutyl ether beta-cyclodextrin sodium is the most important functional excipient because it enables parenteral solubilization of ziprasidone.

Can ziprasidone capsules be formulated without lactose?

Yes. Lactose-free formulations are technically feasible using alternative fillers such as mannitol, microcrystalline cellulose or selected starch systems. The replacement must preserve dissolution, content uniformity and bioequivalence.

Does ziprasidone have biosimilar competition?

No. Ziprasidone is a small-molecule drug, so competition proceeds through generic drug applications rather than biosimilar applications.

What formulation change could create the greatest commercial differentiation?

A formulation that produces reliable exposure without requiring a 500-calorie meal could create the clearest oral differentiation. A long-acting injectable could create greater commercial differentiation but would require substantially more development.

Is SBECD suitable for other injectable drug products?

Yes. SBECD is used as a parenteral solubilizer for multiple poorly water-soluble drugs. Its suitability depends on dose, route, exposure, impurity control, regulatory precedent and the safety profile of the complete formulation.

References

1. U.S. Food and Drug Administration. (2024). Geodon (ziprasidone hydrochloride) capsules and Geodon (ziprasidone mesylate) for injection: Prescribing information. Pfizer Inc. https://labeling.pfizer.com

2. National Library of Medicine. (2024). DailyMed: Ziprasidone hydrochloride capsule. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. U.S. Food and Drug Administration. (2019). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry. https://www.fda.gov

5. U.S. Food and Drug Administration. (2022). Drug products, including biological products, that contain nanomaterials: Guidance for industry. https://www.fda.gov